Cite
HARVARD Citation
Prebet, T. et al. (2018). Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies. British journal of haematology. pp. 735-737. [Online].